Key points are not available for this paper at this time.
Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp TECOS ClinicalTrials.gov number, NCT00790205.).
Green et al. (Mon,) studied this question.